Chronic pulmonary aspergillosis (CPA) is a severe fungal infection with a high morbidity and mortality, and is usually seen in immunocompetent patients with respiratory disorders. Clinical presentation is nonspecific and often overlaps with the symptoms and the radiological pattern caused by the underlying disease. Clinical management of CPA is further hampered by limited information about the epidemiology, disease dynamics, sensitivity and specificity of different mycological tests, mechanisms of antifungal resistance, efficient treatment and management strategies. In order to contribute to a better understanding and to improve CPA patient management and outcome, we established the Chronic Pulmonary Aspergillosis Network (CPAnet), a self-organized multinational research collaboration. Key research priorities, defined by using a modified Delphi process, include the establishment of a multinational web-based registry, the validation of different diagnostic tests, the establishment of a culture collection from samples of patients with proven CPA and the establishment of a consensus on a treatment outcome definition.
Introduction
Estimates suggest that up to 3 million people are affected worldwide by chronic pulmonary aspergillosis (CPA). 1 An estimated 1.2 million of these patients have, or have had, pulmonary TB. 2 Many aspects of this neglected disease are unknown and the disease therefore requires multinational and multicentre cooperation. To meet this challenge, the Chronic Pulmonary Aspergillosis Network (CPAnet) was established in March 2017 to promote clinically oriented research. Several key research priorities were identified that could be addressed without significant funding. Relevant research topics and questions were discussed by a panel of experts and systematically ranked according to their clinical importance in terms of costs and feasibility (Table 1) .
Research focus 1: establishing a multinational web-based registry for CPA
To date, data on CPA are scarce owing to the relatively low incidence of the disease. Current descriptions of disease characteristics such as patient risk factors, disease dynamics, morbidity and mortality are mainly based on retrospective data with a limited number of patients. A multinational registry seems to be a promising approach to gather comprehensive data on a large study population. A web-based approach allows easy access from almost any location worldwide, thus facilitating a multisite study that reflects real-world clinical practice rather than focusing on specific patient populations in single, mainly specialized centres. For physicians, participation in a registry study is often easier to implement in their daily routine and less costly than a formal clinical trial. A registry also provides a certain degree of flexibility for adaptations that might become necessary during the study; e.g. if new diagnostic or treatment approaches for CPA become available requiring broader data collection. Once the conceptual design of the questionnaire is established for the investigators, maintenance of the registry requires comparably little resource in terms of staff, time and fundingan important consideration in studies of chronic diseases with long-term follow-up evaluation. However, the quality of data may vary due to heterogeneous interpretation of the requested items in different institutions, where complex clinical presentations and heterogeneous patient populations complicate clear evaluation. Missing data may also be a concern, especially in retrospective cases, for which certain information might not be available. Clear definitions provided by the study team as well as careful training of research partners before data entry and central data validation by the study team are important elements in reducing errors and ensuring consistency and uniformity of data for valid interpretation.
Approval of the protocol and study documents by the institutional ethics committee of each participating centre will be required. Clinical information collected as part of this study after patient consent has been obtained will be stored on a passwordprotected server at the principal investigator site and kept strictly confidential. Data will be analysed and published in an anonymized form after removal of personal identifiers.
Research focus 2: validating tests for diagnosis of CPA
Mycological evidence is a key criterion to establish CPA diagnosis. 3 However, data about the sensitivity and specificity of different diagnostic tests in CPA patients are limited and often of poor quality. Most microbiological tests used to confirm the presence of Aspergillus infection were often initially developed for use in other forms of Aspergillus-related diseases and frequently perform poorly in CPA populations, with low sensitivity having been demonstrated for culture of sputum and serum galactomannan. 4, 5 The latter is not recommended for CPA diagnosis by the European guideline. Measurement of anti-Aspergillus serum antibodies is recommended for use in CPA diagnosis, as are microscopic examination, culture and PCR or galactomannan analysis of bronchoalveolar lavage (BAL) fluid or histology, culture and PCR analysis of resected lung tissue or transbronchial biopsies. 6, 7 Antibody response to Aspergillus can be measured by different technical approaches, mainly enzyme immunoassay (EIA) and precipitation tests. Precipitins are regarded as a mandatory diagnostic criterion in some countries, but have demonstrated low sensitivity in CPA populations. 6 Reliable use of Aspergillus-specific immunoglobulin G requires accurate cut-offs. Manufacturers' cutoffs are universally based on unpublished data from studies of invasive aspergillosis or allergic bronchopulmonary aspergillosis. 8 Studies have attempted to identify optimal CPA cut-offs, but use existing CPA cohorts as controls, with possible bias in favour of whatever test was primarily used to diagnose that cohort. There is no consensus on whether healthy or diseased controls should be used or how CPA cases should be excluded from diseased control cohorts. 6, 9 Resolving these issues and reaching a consensus on the optimal diagnostic process for CPA is a necessary step in research on this condition.
Large-scale studies directly comparing and evaluating the performance of different diagnostic tests in well-defined patient cohorts are needed. This requires the establishment of a consensus on the appropriate definition of a gold-standard cohort for proven cases. Optimal control cohorts must also be defined and • Gather comprehensive data on a large study population • Use a web-based approach to allow easy access from almost any location worldwide to reflect real-world clinical practice rather than focusing on specific patient populations in single, mainly specialized centres • Provide a certain degree of flexibility for adaptations that might become necessary during the study; e.g. new diagnostic or treatment approaches Research focus 2: validating tests for diagnosis of CPA
• Research focus 3: establishing a culture collection from samples of patients with proven CPA Information on cultured Aspergillus strains isolated from CPA patients is scarce. A Medline database search through PubMed using the terms 'chronic pulmonary aspergillosis' and 'diagnosis' was performed. Only papers published in full text and in English were selected. Case series and studies including .20 CPA cases with information on cultured Aspergillus strains were further evaluated. We retrieved the absolute number and proportion of Aspergillus fumigatus strains identified, the mode of identification used and the existence of azole resistance reported (Table 2) .
We identified 21 studies providing information on cultured Aspergillus strains from CPA patients. Only three studies provided information on methods used for species identification. [10] [11] [12] In these three cases, species identification was based on the morphology, which is nowadays considered to discriminate the Aspergillus species insufficiently. Four studies, one from France and three from the UK, provided results on antifungal susceptibility testing, reporting an azole resistance in 2%, 50%, 53% and 54% of isolates, respectively. [12] [13] [14] [15] Information on the Aspergillus strain and resistance status is of crucial importance in the management of CPA patients, yet this information is not provided by the serological tests used to diagnose most published cases of CPA. Unfortunately some patients are unable to undergo BAL or transbronchial biopsy for mycological/histological analyses; 16 thus, cultures for species identification and susceptibility tests are unavailable in many cases (Table 2) .
Research focus 4: establishing consensus on treatment outcome definition
In 2016 ESCMID, in cooperation with the European Respiratory Society and the European Confederation of Medical Mycology, published guidelines for the diagnosis and management of CPA. IDSA published equivalent guidance in the same year.
3,17 Both Neither guideline provides a treatment outcome definition. Reviewing the current literature regarding the definition of response to treatment indicates that there is a lack of harmonization of endpoints used in the published studies (Table 1) . Most studies used a combination of subjective and objective variables including clinical, radiological and mycological criteria. Clinical parameters, such as quality of life and respiratory symptoms, are subjective variables and the relevance of mycological parameters is hampered by the poor performance of most tests and by the lack of standardization of respiratory sample processing. Some authors highlight their interest in CT scanning for objective assessment of treatment response. 16 It is important to achieve consensus on an outcome definition for clinical trials on CPA, with defined endpoints to evaluate treatment response. Robust, randomized controlled trials are required, with prospectively defined endpoints. The vast majority of published treatment studies are retrospective, non-comparative studies, which complicates the interpretation of the data (Table 3) . Assessment of response to treatment may include the evolution of clinical, mycological and appropriate radiological parameters. 3 
Conclusions
It is increasingly clear that CPA is an important and neglected fungal infection. To date we face a tremendous lack of evidence and many fundamental questions remain unanswered. As the disease is uncommon, collaborative research activities will be needed to meet these challenges. CPAnet as a multinational research collaboration will contribute to this emerging task by promoting clinically oriented research with the aim of improving patient care.
